1 / 22

IMiDs Mechanism of Action and Future Applications

IMiDs Mechanism of Action and Future Applications. A. Keith Stewart Mayo Clinic in Arizona. Scottsdale, Arizona. Rochester, Minnesota. Jacksonville, Florida. IMiD Structures. Side effects. Potency. Potency. Identification of a Primary Target of Thalidomide Teratogenicity.

troy-jenkins
Download Presentation

IMiDs Mechanism of Action and Future Applications

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IMiDs Mechanism of Action and Future Applications A. Keith Stewart Mayo Clinic in Arizona Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida

  2. IMiD Structures Side effects Potency Potency

  3. Identification of a Primary Target of Thalidomide Teratogenicity • Half a century ago, thalidomide was found to be teratogenic, causing multiple birth defects . . . here, we identified cereblon (CRBN) as a thalidomide-binding protein • CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A that is important for limb outgrowth • Thalidomide initiates its teratogenic effects by binding to CRBN and inhibiting the associated ubiquitin ligase activity Takumi Ito, Hideki Ando, Takayuki Suzuki, Toshihiko Ogura, KentaroHotta, Yoshimasa Imamura, Yuki Yamaguchi, Hiroshi Handa. Science. 2010;327:1345-50.

  4. Cereblon • Cereblon on chromosome 3 was first described as associated with human intelligence (Cerebral protein with Lon protease) • Functions in the brain as an ionic channel regulator • Highly conserved from plants to humans, broadly expressed • Regulates AMP kinase in insulin resistance, obesity • Forms an E3ligase complex with DDB1, Cul4A, Roc1

  5. Cereblon Levels are Highest in MM, Leukemias, and Neuroblastoma

  6. Lenalidomide Resistant MM Cells Lack Cereblon MM1.S MM1.S res CRBN b-actin Zhu YX, et al. Blood. 2011;118:4771-9.

  7. Gene Expression Levels of Cereblon Predict Response Rate to Pomalidomide 33% 19% CRBN expression as a percentage of the mean levels in all MM 0% N = Schuster SR,et al. Leuk Res. Jan 2014; 38(1):23-28

  8. Gene Expression Levels of CereblonPredict Overall Survival of Pomalidomide Treated Patients P=0.01 P=0.005 9.1 vs 27 months Schuster SR,et al. Leuk Res. Jan 2014; 38(1):23-28

  9. CRBN Binding Proteins Altered by Lenalidomide Zhu et al. Blood. 2014 Jun 9. [Epub ahead of print]

  10. CRBN Binding Proteins Altered by Lenalidomide Zhu et al. Blood. 2014 Jun 9. [Epub ahead of print]

  11. CRBN Binding Proteins Altered by Lenalidomide Zhu et al. Blood. 2014 Jun 9. [Epub ahead of print]

  12. IKZF1/IRF4/MycDegradation After Lenalidomide Time 3h 6h 24h 48h Len - + - + - + - + IKZF1 IKZF3 IRF4 MYC b-actin

  13. Degradation of Ikaros by Cereblon Binding Small Molecules

  14. Proteasome Inhibitors block IKAROS degradation by Lenalidomide

  15. Sensitivity of MM to Lenalidomide is Correlated with IKAROS Degradation Efficiency Most resistant cell lines Most Sensitive cell lines • MM cell lines with adenoviral vector expressing IKAROS 1 - luciferase fusion gene. Luciferase activity was measured and normalized to cells treated with DMSO

  16. CRBN/IZKF1/IRF4 Expression and Drug Resistance Len Sensitive Len Resistant XG1 MM1.S KMS11 H929 JJN3 EJM OCI-MY5 FR4 SKMM IZKF1 IZKF3 CRBN IRF4 b-actin IZKF1 L208R substitution and codon deletion mutation t(6;14) IgH-IRF4 translocation Zhu et al. Blood. 2014 Jun 9. [Epub ahead of print]

  17. Survival after Pomalidomide/Dexamethasone Zhu et al. Blood. 2014 Jun 9. [Epub ahead of print]

  18. IkarosExpression and Pomalidomide/Dexamethasone Overall survival 7.3 vs 27.2 months p=0.004 Lowest Quartile 0/11 Patients Responded Zhu et al. Blood. 2014 Jun 9. [Epub ahead of print]

  19. 77 gene panel IKZF3 (Aiolis) Mutation: Patient Progressing on Pomalidomide and Dexamethasone Tumor, 702 X, 171 mutation reads (24%) • IKZF3 point mutation (p.Gly157Arg) • exonic, missense, damaging Germline, 462 X, 0 mutation reads

  20. Summary • Cereblonis the IMiD target and accumulates with IMiDbinding • Ikarosis rapidly degraded in presence of IMiD and blocked by bortezomib or carfilzomib in vitro • Low Cereblonand Ikaroslevels may predict response and survival • Resistance can be explained in many cases by disruption of this pathway

  21. Thank you

More Related